Schulte Roth & Zabel represented Deep Track Capital, while Crandon Law represented TORL BioTherapeutics in the transaction.TORL BioTherapeutics announced its closing of an oversubscribed $158 million Series B-2…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
